• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Policy, Organisation and…
  • Quality of Life

Capturing the Broader Value of Antibiotics

STEDI Roadmap
Read more
  • Health Technology Assessment…
  • Economics of Innovation
  • Innovation

Innovation for Health System Efficiency and Improvement

Report picture
Read more
  • Drug Development/R&D
  • Value, Affordability, and…
  • Value based pricing

Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?

6
Read more
  • Antimicrobial Resistance (AMR)
  • Value, Affordability, and…

Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective

Proposal for a Novel Antimicrobial  Subscription
Read more
  • Health Care Systems
  • Policy, Organisation and…
  • Economic Evaluation

Reimagining Prevention for a Healthier, More Prosperous Society

Prev web
Read more
  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 20th April 2023

Around The World in HTAs: Italy – What’s Next?

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Claudio Jommi, Università del Piemonte Orientale Novara, and Martina Garau, OHE, take us to Italy.

Martina 3
Martina Garau
Claudio Jommi
Claudio Jommi
Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Italy_Balloon_AdobeStock_177931475_landscape

The health system in Italy

Italy has a universal national health system, mainly funded by taxes (Italian National Health Service, NHS). The Italian NHS is organised in two levels, national (represented by the Italian Ministry of Health, MoH), and regional (represented by 19 Regions and 2 Autonomous Provinces – Regions hereafter). Regions are allocated a budget for health care from the Central Government and are accountable for health care spending. They can use co-payments, regional taxes and cost-containment policies if the budget is overrun, provided that they guarantee the national benefit package (Livelli Essenziali di Assistenza) defined at central level. Regions regulate, organise and deliver health care, through public and accredited private health care organisations. Policies affecting the relationships between the Central Government and the Regions (including health care funds allocation) are approved by the State-Region Conference (Conferenza Stato-Regioni). Further details of the Italian health system can be found in the series of Health Systems in Transition.

A roadmap for new technologies

The value assessments of medicines and medical devices are managed separately.

Assessment of medical devices

The Italian MoH, AGENAS (National Agency for Regional Health Services), and the Regions are responsible for the assessment of medical devices.  A National HTA Plan for medical devices was envisaged in 2016 and, after a complex preparatory work, released in 2019. The plan has not been implemented so far, but its deployment is expected in the present year. Medical device policies (such as price negotiation, reimbursement, and entry agreement negotiations) are mostly managed by the Regions.

Assessment of medicines

The assessment of new medicines is managed by the HTA & Pharmaceutical Economics Department of AIFA (National Medicines Agency), supported by a Technical Scientific Committee (CTS), that provides scientific advice to Price and Reimbursement (P&R) negotiations, and a P&R Committee (CPR), that negotiates the P&R with the marketing authorization holder, integrating the scientific evaluation with economic aspects. The P&R Request Form, which includes most of the HTA domains, is published on the AIFA’s website.

The assessment of medicines and P&R negotiation relies on a multi-criteria approach. Key criteria considered are: disease burden and target population size, unmet need, added therapeutic value, cost of comparators, budget impact and cost-effectiveness of the new medicine (without official thresholds over the Incremental Cost-Effectiveness Ratio, ICER).

There is evidence of the impact of the target population size and added therapeutic value on the price of orphan medicines (Jommi et al, 2021); of the added therapeutic value on the actual prices of cancer treatments (Russo et al, 2021); and of cost-effectiveness on the percentage difference between the list price requested by manufacturers and the final actual price negotiated (Russo et al, 2023). The P&R dossiers are not published, with the exception of a few advanced therapies.

Pharmaceutical companies may also apply for innovativeness status that provides immediate access to regional markets and a dedicated fund. Drugs innovativeness is appraised on the grounds of unmet therapeutic need, therapeutic added value, and quality of the evidence. All appraisals are published on the AIFA’s website. Recently published evidence showed that the main drivers of the innovativeness status are the added therapeutic value and quality of evidence (Jommi et al, 2023).

Regions usually implement other policies, including co-payment, regional formularies, procurement policies, and actions on prescribing behaviour.

Current challenges of HTA for medicines

The Italian HTA for medicines presents four main challenges:

  • The assessment is affected by the existence of two spending caps (one for drugs procured by health authorities and the other for drugs distributed through the retail market). Silos budgeting is driving the economic assessment which is more focused on drugs budget impact.
  • The second critical aspect is stakeholders’ participation. Patients’ representatives are rarely engaged in the assessment process and involvement of clinicians is affected by very strict conflict of interest rules on one side and low transparency on the other.
  • Fragmentation of the assessment is another problem. Despite medicines are centrally assessed, many regions are used to re-assess drugs to include them into regional formularies. Regional formularies generate delays to access to medicines, whereas a reimbursed drug is very rarely excluded from regional formularies.
  • The last challenge is the current separation of HTA for medicines and other technologies. This is critical since there is not a general HTA framework adopted for all health technologies, and, more specifically, for integrated technologies, like companions.

Next steps for the Italian HTA

Two important changes are expected in the coming year.

The first one is the implementation of the HTA Plan for Medical Devices, that should make the HTA process for medical devices more structured, uniform and centrally-driven.

The second is the expected re-organisation of AIFA . This reform should introduce a new governance , where two committees will be merged into one (Scientific-Economic Committee). This decision was inspired by the expectations of a more rapid assessment and appraisal process compared to the current one, although this process doesn’t take more time in Italy than in other similar markets (EFPIA, 2022).

However, it is not clear if this reform will address the main critical aspects of the assessment process, i.e. a low level of transparency (with the exception of the innovativeness appraisal) and a limited and non-structured stakeholders’ involvement. Furthermore, there is no explicit mention of changes in the cost perspective, i.e. shifting the focus from drug spending to overall health care costs and costs outside the health care sector.

The future political agenda should prioritise these critical aspects, together with a higher integration between HTA for drugs and other health care technologies and a clear positioning on the implementation of the EU Joint Clinical Assessment.

Citations

Jommi, C., Galeone, C. The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency. Pharmacoecon Open. 2023 Feb 10.

Jommi, C., Listorti, E,, Villa, F., et al. Variables affecting pricing of orphan drugs: the Italian case. Orphanet J Rare Dis. 2021 Oct 19;16(1):439.

Russo, P., Zanuzzi, M., Carletto, A., et al. Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service. Pharmacoeconomics. 2023 Jan;41(1):107-117.

Russo, P., Marcellusi, A., Zanuzzi, M., et al. Drug Prices and Value of Oncology Drugs in Italy. Value Health 2021;24(9):1273-1278.

  • Health Technology Assessment…
  • Value, Affordability, and…
  • HTA

Related Insights

HTA Greece-7
  • Insight
  • October 2023

Around The World in HTAs: Greece – Late but with an Optimistic Future

Read more
Slovak Republic
  • Insight
  • September 2023

Around The World in HTAs: The Slovak Republic – Valuing the Future

Read more
this one
  • Insight
  • July 2023

Around The World in HTAs: Egypt – The Road Ahead

Read more
india-balloon-2921973 v3
  • Insight
  • June 2023

Around The World in HTAs: India – Let All Be Healthy

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!